EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY 4.0

Transarterial chemoembolization combined with intra-arterial infusion of sintilimab and bevacizumab for advanced hepatocellular carcinoma: a phase 2 study

Mao-Yuan Mu, Zi-Xiong Chen, Yu-Zhe Cao, Xiao-Bo Fu, Li-Jie Qiu, Han Qi, Fei Gao

Cancer Letters · 2025

DOI: 10.1016/j.canlet.2025.217851 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer Letters, 2025. Verfasst von Mao-Yuan Mu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, P. R. China; State Key Laboratory of Oncology in South China, Guangzhou, Guangdon…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Bevacizumab, Chemoembolization, Therapeutic. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sun Yat-sen University Cancer Center, Guangdong Provincial Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Transarterial chemoembolization (TACE) is an effective locoregional treatment for unresectable hepatocellular carcinoma (HCC). Arterial administration can enhance local drug concentrations while reducing systemic toxicity. The potential synergistic effects of combining locoregional treatments with systemic therapy in advanced HCC warrant further investigation. This phase 2 study (NCT04796025) aimed to evaluate the efficacy and safety of TACE combined with intra-arterial infusion of sintilimab and bevacizumab in patients with advanced HCC. Eligible patients received TACE on demand plus intra-arterial infusion of sintilimab and bevacizumab for four cycles. Maintenance therapy included intravenous administration of sintilimab and bevacizumab until disease progression or unacceptable side effects. The primary outcome was the objective response rate (ORR) based on the modified Response Evaluation Criteria in Solid Tumors (mRECIST). A total of 34 patients (median age, 53 years [IQR 45-59]; 33 men) were enrolled. With a median follow-up of 10.3 months (IQR 5.8-15.6), our results showed a favorable ORR of 70.6 %. The median PFS was calculated as 6.0 months (95 % CI 4.8 - not reached), and the median OS was 12.2 months (95 % CI 9.3 - not reached). Common treatment-related adverse events (any grade) included elevated alanine transaminase (17.6 %), abdominal pain (14.7 %), elevated aspartate aminotransferase (11.8 %), and hypertension (11.8 %). Grade 3 adverse events included hypertension (2.9 %) and gastrointestinal hemorrhage (8.8 %). No serious treatment-related adverse events were observed. TACE combined with sintilimab and bevacizumab has demonstrated a favorable ORR and promising efficacy in advanced HCC, with manageable side effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsBevacizumabChemoembolization, TherapeuticAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsHumansMiddle AgedMaleFemaleInfusions, Intra-ArterialTreatment Outcome

Stichwörter der Autor:innen

BevacizumabHepatocellular carcinomaProgrammed death protein 1Transarterial chemoembolization

Substanzen

BevacizumabAntibodies, Monoclonal, Humanizedsintilimab

Autor:innen und Institutionen

  • Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, P. R. China; State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, P. R. China; Guangdong Provincial Clinical Research Center…

Förderung

  • Sun Yat-sen University Cancer Center
  • Guangdong Provincial Natural Science Foundation

Zitieren

APA

Mu, M. Y., Chen, Z. X., Cao, Y. Z., Fu, X. B., Qiu, L. J., Qi, H., & Gao, F. (2025). Transarterial chemoembolization combined with intra-arterial infusion of sintilimab and bevacizumab for advanced hepatocellular carcinoma: a phase 2 study. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.217851

Vancouver

Mu MY, Chen ZX, Cao YZ, Fu XB, Qiu LJ, Qi H, et al. Transarterial chemoembolization combined with intra-arterial infusion of sintilimab and bevacizumab for advanced hepatocellular carcinoma: a phase 2 study. Cancer Letters. 2025. doi:10.1016/j.canlet.2025.217851

BibTeX
@article{Mu2025,
  author = {Mu, Mao-Yuan and Chen, Zi-Xiong and Cao, Yu-Zhe and Fu, Xiao-Bo and Qiu, Li-Jie and Qi, Han and Gao, Fei},
  title = {Transarterial chemoembolization combined with intra-arterial infusion of sintilimab and bevacizumab for advanced hepatocellular carcinoma: a phase 2 study},
  journal = {Cancer Letters},
  year = {2025},
  doi = {10.1016/j.canlet.2025.217851}
}
Kostenlos starten →